TMCnet News
RNA INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Prosensa Holding N.V. in Connection With the Fairness of the Sale of the Company to BioMarin Pharmaceutical Inc. -- RNANEW YORK --(Business Wire)-- Levi & Korsinsky is investigating the Board of Directors of Prosensa Holding N.V. ("Prosensa" or "the Company") (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to BioMarin Pharmaceutical Inc. Click here to learn more about the investigation: http://zlk.9nl.com/prosensaholding-rna. Under the terms of the transaction, Prosensa shareholders will receive a $17.75 for each share of Prosensa stock they own. The investigation concerns whether the Board of Prosensa breached their fiduciary duties to stockholders byfailing to adequately shop the Company before agreeing to enter into this transaction, and whether BioMarin Pharmaceutical Inc. is underpaying for Prosensa shares. If you own Prosensa common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/prosensaholding-rna. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
|
